About XERESE®

Xerese has been proven to speed up healing and reduce the tenderness of an outbreak.

Clinical efficacy: XERESE vs acyclovir and placebo

Clinical Proof statistics

It’s important to remember that XERESE is not a cure—there is no cure for cold sores.3 But, it can help treat the symptoms, reduce severity, and speed healing time in some patients.1,2

XERESE has a potential for irritation and contact sensitization.3

*A multicenter, randomized, double-blind, active and placebo-controlled study involving 2,437 patients with a history of herpes simplex labialis, in which 1,443 received treatment; 601 were treated with XERESE. Patients were randomized to self-initiate treatment with XERESE, 5% acyclovir in XERESE vehicle, or XERESE vehicle (placebo) within an hour of the first signs and symptoms.

†A double-blind, randomized, placebo-controlled study involving 417 patients with a history of recurrent herpes labialis after exposure to sunlight, in which 380 received treatment; 50 were treated with XERESE. Patients were randomized to initiate treatment with XERESE or placebo the second day after UV radiation exposure.

‡BRING THIS COUPON TO YOUR PHARMACIST FOR COPAY SAVINGS.

TO THE PATIENT:
You must present this coupon along with your prescription to participate in this program. You must activate this coupon before using by calling 1-866-686-0122, texting "XERESE" to 24109, or by visiting https://copaysavingsprogram.com/110/Xerese.

When you use this coupon you are certifying that you understand and agree to the program rules, regulations, eligibility requirements, and terms and conditions.

This offer is not valid for any person eligible for reimbursement of prescriptions, in whole or in part, by any federal, state, or other governmental programs, including, but not limited to, Medicare (including Medicare Advantage and Part A, B, and D plans), Medicaid, TRICARE, Veterans Administration or Department of Defense health coverage, CHAMPUS, the Puerto Rico Government Health Insurance Plan, or any other federal or state health care programs or for anyone 65 years of age or older without commercial insurance.

TO THE PHARMACIST:
When you use this coupon, you are certifying that you have not submitted and will not submit a claim for reimbursement under any federal, state, or other governmental programs for this prescription.

Submit the claim to the primary Third Party Payer first, then submit the balance due to DST Pharmacy Solutions as a Secondary Payer as a copay only billing using BIN 019158 and a valid Other Coverage Code (e.g. 8). Reimbursement will be received from DST Pharmacy Solutions.

Cash paying patients, submit this claim to DST Pharmacy Solutions using BIN 019158. A valid Other Coverage Code(e.g. 1) is required.

For any questions regarding DST Pharmacy Solutions online processing, please call the Help Desk at 1-844-373-0987

This offer is only valid for patients with commercial insurance and eligible uninsured patients.

Cash Discount Cards and other non-insurance plans are not valid as primary under this offer. If the patient is eligible for drug benefits under any such program, the patient cannot use this offer.

When you use this coupon you are certifying that you have not submitted and will not submit a claim for reimbursement under any federal, state, or other governmental programs, including, but not limited to, Medicare (including Medicare Advantage and Part A, B, and D plans), Medicaid, TRICARE, Veterans Administration or Department of Defense health coverage, CHAMPUS, the Puerto Rico Government Health Insurance Plan, or any other federal or state health care programs. This offer is not valid for any person eligible for reimbursement of prescriptions in whole or in part, by any of these programs.

By accepting this coupon and submitting claims for any of the products specified here in you agree to the program terms and conditions, which are posted at www.xeresesavings.com.

This offer is not valid for any person eligible for reimbursement of prescriptions, in whole or in part, by any federal, state, or other governmental programs, including, but not limited to, Medicare (including Medicare Advantage and Part A, B, and D plans), Medicaid, TRICARE, Veterans Administration or Department of Defense health coverage, CHAMPUS, the Puerto Rico Government Health Insurance Plan, or any other federal or state health care programs.

OraPharma affiliated entities reserves the right to rescind, revoke, terminate, or amend this offer at any time, without notice. This offer expires on December 31, 2019.

REFERENCES: 1. Evans TG, Bernstein DI, Raborn GW, Harmenberg J, Kowalski J, Spruance SL. Double-blind, randomized, placebo-controlled study of topical 5% acyclovir-1% hydrocortisone cream (ME-609) for treatment of UV radiation-induced herpes labialis. Antimicrob Agents Chemother. 2002;46:1870-1874. 2. Hull CM, Harmenberg J, Arlander E, et al. Early treatment of cold sores with topical ME-609 decreases the frequency of ulcerative lesions: a randomized, double-blind, placebo-controlled, patient-initiated clinical trial. J Am Acad Dermatol. 2011;64(4):696.e1-11. 3. XERESE® (acyclovir and hydrocortisone) cream 5%/1% Prescribing Information. January, 2014.

XERESE® (acyclovir and hydrocortisone) cream 5%/1% is indicated for the early treatment of recurrent herpes labialis (cold sores) to reduce the likelihood of ulcerative cold sores and to shorten the lesion healing time in patients 6 years of age and older.
 

Important Safety Information


INDICATION

XERESE® (acyclovir and hydrocortisone) cream 5%/1% is indicated for the early treatment of recurrent herpes labialis (cold sores) to reduce the likelihood of ulcerative cold sores and to shorten the lesion healing time in patients 6 years of age and older.

Important safety information
  • XERESE (acyclovir and hydrocortisone) cream 5%/1% is intended for cutaneous use only, on the lips and around the mouth. XERESE should not be used in the eye, inside the mouth or nose, or on the genitals.
  • Systemic exposure to acyclovir and hydrocortisone following topical administration is minimal. However, caution should be exercised when XERESE is administered to women who are pregnant or nursing. The benefit of XERESE has not been adequately assessed in immunocompromised patients.
  • XERESE has a potential for irritation and contact sensitization.
  • In clinical trials, the most common adverse reactions in the area of the application site included drying or flaking of the skin; burning or tingling following application; erythema; pigmentation changes; application site reaction including signs and symptoms of inflammation. Each event occurred in less than 1% of patients.
  • Patients should be encouraged to seek medical advice when a cold sore fails to heal within 2 weeks.

To report SUSPECTED ADVERSE REACTIONS, contact Bausch Health LLC at 1-800-321-4576 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Click here for full Prescribing Information.